158 related articles for article (PubMed ID: 36371791)
1. To what extent does the use of crosswalks instead of EQ-5D value sets impact reimbursement decisions?: a simulation study.
Ben ÂJ; van Dongen JM; Finch AP; Alili ME; Bosmans JE
Eur J Health Econ; 2023 Nov; 24(8):1253-1270. PubMed ID: 36371791
[TBL] [Abstract][Full Text] [Related]
2. Cost-Utility Analysis Using EQ-5D-5L Data: Does How the Utilities Are Derived Matter?
Yang F; Devlin N; Luo N
Value Health; 2019 Jan; 22(1):45-49. PubMed ID: 30661633
[TBL] [Abstract][Full Text] [Related]
3. Comparing the EQ-5D-5L crosswalks and value sets for England, the Netherlands and Spain: Exploring their impact on cost-utility results.
Ben Â; Finch AP; van Dongen JM; de Wit M; van Dijk SEM; Snoek FJ; Adriaanse MC; van Tulder MW; Bosmans JE
Health Econ; 2020 May; 29(5):640-651. PubMed ID: 32059078
[TBL] [Abstract][Full Text] [Related]
4. Comparing the UK EQ-5D-3L and English EQ-5D-5L Value Sets.
Mulhern B; Feng Y; Shah K; Janssen MF; Herdman M; van Hout B; Devlin N
Pharmacoeconomics; 2018 Jun; 36(6):699-713. PubMed ID: 29476363
[TBL] [Abstract][Full Text] [Related]
5. Estimating Cost-Effectiveness Using Alternative Preference-Based Scores and Within-Trial Methods: Exploring the Dynamics of the Quality-Adjusted Life-Year Using the EQ-5D 5-Level Version and Recovering Quality of Life Utility Index.
Franklin M; Hunter RM; Enrique A; Palacios J; Richards D
Value Health; 2022 Jun; 25(6):1018-1029. PubMed ID: 35667775
[TBL] [Abstract][Full Text] [Related]
6. Mapping Sri Lankan EQ-5D-3L to EQ-5D-5L Value Sets.
Kularatna S; Chen G; Byrnes J; Scuffham PA
Value Health Reg Issues; 2017 May; 12():20-23. PubMed ID: 28648311
[TBL] [Abstract][Full Text] [Related]
7. A Comparison of Generic and Condition-Specific Preference-Based Measures Using Data From Nivolumab Trials: EQ-5D-3L, Mapping to the EQ-5D-5L, and European Organisation for Research and Treatment of Cancer Quality of Life Utility Measure-Core 10 Dimensions.
Shaw JW; Bennett B; Trigg A; DeRosa M; Taylor F; Kiff C; Ntais D; Noon K; King MT; Cocks K
Value Health; 2021 Nov; 24(11):1651-1659. PubMed ID: 34711366
[TBL] [Abstract][Full Text] [Related]
8. EQ-5D-5L is More Responsive than EQ-5D-3L to Treatment Benefit of Cataract Surgery.
Gandhi M; Ang M; Teo K; Wong CW; Wei YC; Tan RL; Janssen MF; Luo N
Patient; 2019 Aug; 12(4):383-392. PubMed ID: 30607809
[TBL] [Abstract][Full Text] [Related]
9. Assessing the Impact of EQ-5D Country-specific Value Sets on Cost-utility Outcomes.
van Dongen JM; Jornada Ben Â; Finch AP; Rossenaar MMM; Biesheuvel-Leliefeld KEM; Apeldoorn AT; Ostelo RWJG; van Tulder MW; van Marwijk HWJ; Bosmans JE
Med Care; 2021 Jan; 59(1):82-90. PubMed ID: 33201085
[TBL] [Abstract][Full Text] [Related]
10. Parallel Valuation of the EQ-5D-3L and EQ-5D-5L by Time Trade-Off in Hungary.
Rencz F; Brodszky V; Gulácsi L; Golicki D; Ruzsa G; Pickard AS; Law EH; Péntek M
Value Health; 2020 Sep; 23(9):1235-1245. PubMed ID: 32940242
[TBL] [Abstract][Full Text] [Related]
11. Parallel Valuation: A Direct Comparison of EQ-5D-3L and EQ-5D-5L Societal Value Sets.
Law EH; Pickard AS; Xie F; Walton SM; Lee TA; Schwartz A
Med Decis Making; 2018 Nov; 38(8):968-982. PubMed ID: 30403577
[TBL] [Abstract][Full Text] [Related]
12. Is EQ-5D-5L Better Than EQ-5D-3L Over Time? A Head-to-Head Comparison of Responsiveness of Descriptive Systems and Value Sets from Nine Countries.
Janssen MF; Buchholz I; Golicki D; Bonsel GJ
Pharmacoeconomics; 2022 Nov; 40(11):1081-1093. PubMed ID: 35930137
[TBL] [Abstract][Full Text] [Related]
13. EQ-5D-5L measurement properties are superior to EQ-5D-3L across the continuum of health using US value sets.
Jiang R; Rand K; Kuharic M; Pickard AS
Health Qual Life Outcomes; 2022 Sep; 20(1):134. PubMed ID: 36085228
[TBL] [Abstract][Full Text] [Related]
14. EQ-5D-5L versus EQ-5D-3L: The Impact on Cost Effectiveness in the United Kingdom.
Hernandez Alava M; Wailoo A; Grimm S; Pudney S; Gomes M; Sadique Z; Meads D; O'Dwyer J; Barton G; Irvine L
Value Health; 2018 Jan; 21(1):49-56. PubMed ID: 29304940
[TBL] [Abstract][Full Text] [Related]
15. Interim EQ-5D-5L Value Set for Poland: First Crosswalk Value Set in Central and Eastern Europe.
Golicki D; Niewada M; Hout BV; Janssen MF; Pickard AS
Value Health Reg Issues; 2014 Sep; 4():19-23. PubMed ID: 29702801
[TBL] [Abstract][Full Text] [Related]
16. EuroQol (EQ-5D-5L) Validity in Assessing the Quality of Life in Adults With Asthma: Cross-Sectional Study.
Hernandez G; Garin O; Dima AL; Pont A; Martí Pastor M; Alonso J; Van Ganse E; Laforest L; de Bruin M; Mayoral K; Serra-Sutton V; Ferrer M;
J Med Internet Res; 2019 Jan; 21(1):e10178. PubMed ID: 30672744
[TBL] [Abstract][Full Text] [Related]
17. Comparing the psychometric properties of the EQ-5D-3L and EQ-5D-5L descriptive systems and utilities in atopic dermatitis.
Koszorú K; Hajdu K; Brodszky V; Bató A; Gergely LH; Kovács A; Beretzky Z; Sárdy M; Szegedi A; Rencz F
Eur J Health Econ; 2023 Feb; 24(1):139-152. PubMed ID: 35412162
[TBL] [Abstract][Full Text] [Related]
18. How the EQ-5D utilities are derived matters in Chinese diabetes patients: a comparison based on different EQ-5D scoring functions for China.
Pan CW; Zhang RY; Luo N; He JY; Liu RJ; Ying XH; Wang P
Qual Life Res; 2020 Nov; 29(11):3087-3094. PubMed ID: 32533422
[TBL] [Abstract][Full Text] [Related]
19. A vision 'bolt-on' increases the responsiveness of EQ-5D: preliminary evidence from a study of cataract surgery.
Gandhi M; Ang M; Teo K; Wong CW; Wei YC; Tan RL; Janssen MF; Luo N
Eur J Health Econ; 2020 Jun; 21(4):501-511. PubMed ID: 31902023
[TBL] [Abstract][Full Text] [Related]
20. Interim value set for the EQ-5D-5L in Iran using the Crosswalk method.
Ameri H; Safari H; Yousefi M; Bagheri Faradonbeh S; Goudarzi R; Soofi M
Med J Islam Repub Iran; 2020; 34():121. PubMed ID: 33437717
[No Abstract] [Full Text] [Related]
[Next] [New Search]